ResearchMoz

Pediatric Vaccines Market to 2017- Strategic Focus on Partnering as Licensing and Co-Development Accounted for 69% of Deal-Making Activity from 2004-2011

GBI Research
Published Date » 2012-03-14
No. Of Pages » 127
 
   
 GBI Research, the leading business intelligence provider, has released its latest research, “Pediatric Vaccines Market to 2017Strategic Focus on Partnering as Licensing and Co-Development Accounted for 69% of Deal-Making Activity from 2004-2011”, which provides insights into global pediatric vaccines market forecast until 2017. The report provides an in-depth analysis of six vaccines which include hepatitis A, hepatitis B, polio, rotavirus, Mumps, Measles and Rubella (MMR) and Diphtheria, Tetanus and Pertussis (DTaP). The report also examines the immunization schedules for the covered vaccines. In addition, the report also includes insights into the vaccines Research and Development (R&D) pipeline.  
   
 The report is built using data and information...
Table of Contents

1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 6
1.2 List of Figures 8

2 Pediatric Vaccines Market to 2017 - Introduction 10
2.1 GBI Research Report Guidance 11

3 Pediatric Vaccines Market to 2017 - Market Overview 12
3.1 Vaccine Preventable Diseases 12
3.2 Vaccine Manufacturing Process 13
3.3 Determinants of Immunization Coverage 13
3.3.1 Immunization Programs 13
3.3.2 Public Private Partnerships 14
3.3.3 Production Capacity 14
3.3.4 Reimbursements 14

4 Pediatric Vaccines Market to 2017 - Global Vaccine Market 15
4.1 Market Forecasts 15
4.1.1 Market Share by Disease Sector 16
4.1.2 Market Share by Geography 17
4.2 Average Cost of Vaccination per Child 17
4.3 Target Population 18
4.3.1 Immunization Coverage 19
4.4 Drivers and Barriers of the Pediatric Vaccines Market 20
4.4.1 Drivers for Pediatric Vaccine Market 20
4.4.2 Barriers for Pediatric Vaccines Market 21

5 Global Pediatric Vaccines Market to 2017 - Geographical Landscape 22
5.1 The US 22
5.1.1 Market Overview 22
5.1.2 Market Forecasts 22
5.1.3 Average Cost of Vaccination 23
5.1.4 Immunization Coverage 25
5.1.5 Immunization Schedule 26
5.1.6 Regulatory Framework 27
5.1.7 Vaccine Procurement 28
5.2 Top Five Countries of Europe 29
5.2.1 Market Overview 29
5.2.2 Market Forecasts 29
5.2.3 Average Cost of Vaccination per Child 30
5.2.4 Immunization Coverage 32
5.2.5 The UK 33
5.2.6 France 34
5.2.7 Germany 35
5.2.8 Italy 36
5.2.9 Spain 37
5.3 Rest of the World 38
5.3.1 Market Overview 38
5.3.2 Market Forecasts 38
5.3.3 Average Cost of Vaccination per Child 39
5.3.4 Immunization Coverage 41
5.3.5 Immunization Schedule 42
5.3.6 Regulatory Framework 42
5.3.7 Vaccine Procurement 42

6 Global Pediatric Vaccines Market to 2017 - Therapeutic Landscape 43
6.1 Hepatitis A 43
6.1.1 Overview 43
6.1.2 Market Forecasts 43
6.1.3 Average Cost of Vaccination 44
6.1.4 Target Population 45
6.1.5 Marketed Products for Hepatitis A 46
6.2 Hepatitis B 48
6.2.1 Overview 48
6.2.2 Market Forecasts 49
6.2.3 Average Cost of Vaccination 50
6.2.4 Target Population 51
6.2.5 Marketed Products for Hepatitis B 52
6.3 Polio 55
6.3.1 Overview 55
6.3.2 Market Forecasts 55
6.3.3 Average Cost of Vaccination 56
6.3.4 Target Population 57
6.3.5 Marketed Products for Polio 58
6.4 Rotavirus 59
6.4.1 Overview 59
6.4.2 Market Forecasts 59
6.4.3 Average Cost of Vaccination 60
6.4.4 Target Population 61
6.4.5 Product Analysis 62
6.4.6 Marketed Products for Rotavirus 62
6.5 DTaP 64
6.5.1 Overview 64
6.5.2 Market Forecasts 64
6.5.3 Average Cost of Vaccination 65
6.5.4 Target Population 66
6.5.5 Marketed Products for DTaP 67
6.6 MMR 69
6.6.1 Overview 69
6.6.2 Market Forecasts 69
6.6.3 Average Cost of Vaccination 70
6.6.4 Target Population 71
6.6.5 Marketed Products for MMR 72

7 Global Pediatric Vaccines Market to 2017 - Product Pipeline Analysis 74
7.1 Research and Development Pipeline by Phase 74
7.2 Research and Development Pipeline by Indication 75
7.3 Research and Development Pipeline - Hepatitis A Vaccines 76
7.3.1 Overview 76
7.3.2 Pipeline by Clinical Phases of Development 77
7.4 Research and Development Pipeline - Hepatitis B Vaccines 77
7.4.1 Overview 77
7.4.2 Pipeline by Clinical Phases of Development 78
7.5 Research and Development Pipeline - Polio Vaccines 83
7.5.1 Overview 83
7.5.2 Pipeline by Clinical Phases of Development 84
7.6 Research and Development Pipeline - Rotavirus Vaccines 86
7.6.1 Overview 86
7.6.2 Pipeline by Clinical Phases of Development 87
7.7 Research and Development Pipeline - DTaP Vaccines 88
7.7.1 Overview 88
7.7.2 Pipeline by Clinical Phases of Development 89
7.8 Research and Development Pipeline - MMR Vaccines 92
7.8.1 Overview 92
7.8.2 Pipeline by Clinical Phases of Development 93

8 Global Pediatric Vaccines Market - Competitive Landscape 94
8.1 Overview 94
8.2 Company Profiling 94
8.2.1 Novartis 94
8.2.2 GlaxoSmithKline (GSK) 96
8.2.3 Sanofi Pasteur MSD 97
8.2.4 Merck 99
8.2.5 Pfizer 100

9 Global Pediatric Vaccines Market to 2017 - Strategic Consolidations 102
9.1 Segmentation by Type 102
9.2 Segmentation by Year 103
9.3 Mergers and Acquisitions 104
9.3.1 Overview 104
9.3.2 M&A Deals by Indication 105
9.3.3 M&A Deals by Year 106
9.3.4 M&A Deals by Geography 107
9.3.5 M&A Deals by Value 108
9.3.6 Major Mergers and Acquisitions (M&A) 109
9.4 Licensing Agreements 110
9.4.1 Overview 110
9.4.2 Licensing Agreements by Indication 110
9.4.3 Licensing Agreements by Year 112
9.4.4 Licensing Agreements by Geography 113
9.4.5 Licensing Agreements by Value 114
9.4.6 Major Licensing Agreements 115
9.5 Co-Development Deals 117
9.5.1 Overview 117
9.5.2 Co-Development Deals by Indication 117
9.5.3 Co-Development Deals by Year 118
9.5.4 Co-Development Deals by Geography 119
9.5.5 Major Co-Development Deals 120

10 Global Pediatric Vaccines Market to 2017 - Appendix 122
10.1 Market Definitions 122
10.2 Abbreviations 122
10.3 Research Methodology 123
10.3.1 Global Pediatric Vaccines Market 123
10.3.2 Geographical Landscape 124
10.3.3 Therapeutic Landscape 125
10.3.4 Competitive Landscape 125
10.3.5 Pipeline Analysis 126
10.3.6 Strategic Consolidations 126
10.4 Contact Us 126
10.5 Disclaimer 126
10.6 Sources 127

List of Tables


Table 1: Pediatric Vaccine Market, Global, Vaccine Preventable Diseases, 2011 12
Table 2: Pediatric Vaccines Market, Global, Revenue Forecasts ($bn), 2007-2017 15
Table 3: Pediatric Vaccines Market, Global, Target Population (million), 2007-2017 18
Table 4: Pediatric Vaccines Market, Global, Immunization Coverage, (%), 2008-2010 19
Table 5: Pediatric Vaccines Market, The US, Revenue Forecasts ($bn), 2007-2017 22
Table 6: Pediatric Vaccines Market, The US, Average Cost of Vaccination Per Child ($), 2011 24
Table 7: Pediatric Vaccines Market, The US, Immunization Coverage, (%), 2008-2010 25
Table 8: Pediatric Vaccines Market, Top Five Countries of Europe, Average Cost of Vaccination Per Child ($), 2010 31
Table 9: Pediatric Vaccines Market, Top Five Countries of Europe, Immunization Coverage, %, 2008-2010 32
Table 10: Pediatric Vaccines Market, Rest of the World, Revenue Forecasts ($bn), 2007-2017 39
Table 11: Pediatric Vaccines Market, Rest of the World, Average Cost of Vaccination Per Child ($), 2011 40
Table 12: Pediatric Vaccines Market, Rest of the World, Immunization Coverage, (%), 2008-2010 41
Table 13: Hepatitis A Vaccines Market, Global, Revenue Forecasts ($m), 2007-2017 43
Table 14: Hepatitis A Vaccines Market, Global, Average Cost of Vaccination($) , 2007-2017 44
Table 15: Hepatitis A Vaccines Market, Global, Target Population (million), 2007-2017 45
Table 16: Hepatitis B Vaccines Market, Global, Revenue Forecasts ($m), 2007-2017 49
Table 17: Hepatitis B Vaccines Market, Global, Average Cost of Vaccination, ($), 2007-2017 50
Table 18: Hepatitis B Vaccines Market, Global, Target Population (million) , 2007-2017 51
Table 19: Polio Vaccines Market, Global, Revenue Forecasts ($m), 2007-2017 55
Table 20: Polio Vaccines Market, Global, Average Cost of Vaccination ($) , 2007-2017 56
Table 21: Polio Vaccines Market, Global, Target Population (million), 2007-2017 57
Table 22: Rotavirus Vaccines Market, Global, Revenue Forecasts ($bn), 2007-2017 59
Table 23: Rotavirus Vaccines Market, Global, Average Cost of Vaccination ($), 2007-2017 60
Table 24: Rotavirus Vaccines Market, Global, Target Population (million), 2007-2017 61
Table 25: Rotavirus Vaccines Market, Global, Comparison of Key Products, 2011 62
Table 26: DTaP Vaccines Market, Global, Revenue Forecasts ($m), 2007-2017 64
Table 27: DTaP Vaccines Market, Global, Average Cost of Vaccination, ($), 2007-2017 65
Table 28: DTaP Vaccines Market, Global, Target Population (million), 2007-2017 66
Table 29: MMR Vaccines Market, Global, Revenue Forecasts ($bn), 2007–2017 69
Table 30: MMR Vaccines Market, Global, Average Cost of Vaccination($), 2007–2017 70
Table 31: MMR Vaccines Market, Global, Target Population (million), 2007-2017 71
Table 32: Pediatric Vaccines Market, Global, Pipeline Molecules by Phase, (%), 2011 74
Table 33: Pediatric Vaccines Market, Global, Pipeline Molecules by Indication, (%), 2011 75
Table 34: Hepatitis A Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011 76
Table 35: Hepatitis A Therapeutics Market, Global, Preclinical Pipeline Molecules, 2011 77
Table 36: Hepatitis A Therapeutics Market, Global, Phase III Molecules, 2011 77
Table 37: Hepatitis B Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011 78
Table 38: Hepatitis B Therapeutics Market, Global, Preclinical Pipeline Molecules, 2011 78
Table 39: Hepatitis B Therapeutics Market, Global, Phase I Molecules, 2011 79
Table 40: Hepatitis B Therapeutics Market, Global, Phase II Molecules, 2011 80
Table 41: Hepatitis B Therapeutics Market, Global, Phase III Molecules, 2011 82
Table 42: Hepatitis B Therapeutics Market, Global, NDA Filed Molecules, 2011 83
Table 43: Polio Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011 84
Table 44: Polio Therapeutics Market, Global, Phase II Molecules, 2011 84
Table 45: Polio Therapeutics Market, Global, Phase III Molecules, 2011 85
Table 46: Rotavirus Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011 86
Table 47: Rotavirus Therapeutics Market, Global, Pre-Clinical Molecules, 2011 87
Table 48: Rotavirus Therapeutics Market, Global, Phase I Molecules, 2011 87
Table 49: Rotavirus Therapeutics Market, Global, Phase II Molecules, 2011 87
Table 50: Rotavirus Therapeutics Market, Global, Phase III Molecules, 2011 87
Table 51: DTaP Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011 88
Table 52: DTaP Therapeutics Market, Global, Preclinical Molecules, 2011 89
Table 53: DTaP Therapeutics Market, Global, Phase I Molecules, 2011 89
Table 54: DTaP Therapeutics Market, Global, Phase II Molecules, 2011 90
Table 55: DTaP Therapeutics Market, Global, Phase III Molecules, 2011 91
Table 56: DTAP Therapeutics Market, Global, NDA Filed Molecules, 2011 91
Table 57: MMR Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011 92
Table 58: MMR Therapeutics Market, Global, Preclinical Molecules, 2011 93
Table 59: MMR Therapeutics Market, Global, Phase II Molecules, 2011 93
Table 60: MMR Therapeutics Market, Global, Phase II Molecules 93
Table 61: Pediatric Vaccines Market, Global, Deals by Type, (%), 2004-2011 102
Table 62: Pediatric Vaccines Market, Global, Deals by Geography, (%), 2004-2011 103
Table 63: Pediatric Vaccines Market, Global, M&A Deals, 2004-2011 104
Table 64: Pediatric Vaccines Market, Global, M&A Deals by Indication (%), 2004-2011 105
Table 65: Pediatric Vaccines Market, Global, M&A Deals by Year, 2004-2011 106
Table 66: Pediatric Vaccines Market, Global, M&A Deals by Geography (%), 2004-2011 107
Table 67: Pediatric Vaccines Market, Global, M&A Deals by Value (%), 2004-2011 108
Table 68: Pediatric Vaccines Market, Global, Major M&A Deals, 2004–2011 109
Table 69: Pediatric Vaccines Market, Global, Licensing Agreements by Indication (%), 2004-2011 111
Table 70: Pediatric Vaccines Market, Global, Licensing Agreements by Year, 2004-2011 112
Table 71: Pediatric Vaccines Market, Global, Licensing Agreements by Geography (%), 2004-2011 113
Table 72: Pediatric Vaccines Market, Global, Licensing Agreements by Value (%), 2004-2011 114
Table 73: Pediatric Vaccines Market, Global, Major Licensing Deals, 2004–2011 115
Table 74: Pediatric Vaccines Market, Global, Co-Development Deals by Indication (%), 2004-2011 117
Table 75: Pediatric Vaccines Market, Global, Co-Development Deals by Year, 2004-2011 118
Table 76: Pediatric Vaccines Market, Global, Co-Development Deals by Geography, 2004-2011 119
Table 77: Pediatric Vaccines Market, Global, Major Co-Development Deals, 2004–2011 120

List of Figures


Figure 1:  Pediatric Vaccines Market, Global, Manufacturing Process, 2011 13
Figure 2: Pediatric Vaccines Market, Global, Revenue Forecasts ($bn), 2007-2017 15
Figure 3: Pediatric Vaccines Market, Global, Market Share by Disease Segment, 2010 16
Figure 4: Pediatric Vaccines Market, Global, Market Share by Geography, 2010 17
Figure 5: Pediatric Vaccines Market, Global, Target Population (million), 2007-2017 18
Figure 6: Pediatric Vaccines Market, Global, Immunization Coverage, (%), 2008-2010 19
Figure 7: Pediatric Vaccines Market, Global, Growth Drivers and Barriers, 2011 20
Figure 8: Pediatric Vaccines Market, The US, Revenue Forecasts ($bn), 2007-2017 22
Figure 9: Pediatric Vaccines Market, The US, Average Cost of Vaccination Per Child ($), 2011 23
Figure 10: Pediatric Vaccines Market, The US, Immunization Coverage, (%), 2008-2010 25
Figure 11: Pediatric Vaccines Market, The US, Immunization Schedule, 2011 26
Figure 12: Pediatric Vaccines Market. The US, Vaccine Development and Approval Process, 2011 27
Figure 13: Pediatric Vaccines Market, The US, Distribution of Vaccine Procurement (%) , 2011 28
Figure 14: Pediatric Vaccines Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2007-2017 29
Figure 15: Pediatric Vaccines Market, Top Five Countries of Europe, Average Cost of Vaccination Per Child ($), 2011 30
Figure 16: Pediatric Vaccines Market, Top Five Countries of Europe, Immunization Coverage, (%), 2008-2010 32
Figure 17: Pediatric Vaccines Market, The UK, Immunization Schedule, 2011 33
Figure 18: Pediatric Vaccines Market, France, Immunization Schedule, 2011 34
Figure 19: Pediatric Vaccines Market, Germany, Immunization Schedule, 2011 35
Figure 20: Pediatric Vaccines Market, Italy, Immunization Schedule, 2011 36
Figure 21: Pediatric Vaccines Market, Spain, Immunization Schedule, 2011 37
Figure 22: Pediatric Vaccines Market, Rest of the World, Revenue Forecasts ($bn), 2007-2017 38
Figure 23: Pediatric Vaccines Market, Rest of the World, Average Cost of Vaccination Per Child ($), 2011 39
Figure 24: Pediatric Vaccines Market, Rest of the World, Immunization Coverage, (%), 2008-2010 41
Figure 25: Hepatitis A Vaccines Market, Global, Revenue Forecasts ($m), 2007-2017 43
Figure 26: Hepatitis A Vaccines Market, Global, Average Cost of Vaccination ($), 2007-2017 44
Figure 27: Hepatitis A Vaccines Market, Global, Target Population (million), 2007-2017 45
Figure 28: Hepatitis B Vaccines Market, Global, Revenue Forecasts ($m), 2007-2017 49
Figure 29: Hepatitis B Vaccines Market, Global, Average Cost of Vaccination, ($), 2007-2017 50
Figure 30: Hepatitis B Vaccines Market, Global, Target Population (million) , 2007-2017 51
Figure 31: Polio Vaccines Market, Global, Revenue Forecasts ($m), 2007-2017 55
Figure 32: Polio Vaccines Market, Global, Average Cost of Vaccination, ($), 2007-2017 56
Figure 33: Polio Vaccines Market, Global, Target Population (million), 2007-2017 57
Figure 34: Rotavirus Vaccines Market, Global, Revenue Forecasts ($bn), 2007-2017 59
Figure 35: Rotavirus Vaccines Market, Global, Average Cost of Vaccination ($), 2007-2017 60
Figure 36: Rotavirus Vaccines Market, Global, Target Population (million), 2007-2017 61
Figure 37: DTaP Vaccines Market, Global, Revenue Forecasts ($m), 2007-2017 64
Figure 38: DTaP Vaccines Market, Global, Average Cost of Vaccination($), 2007-2017 65
Figure 39: DTaP Vaccines Market, Global, Target Population (million), 2007-2017 66
Figure 40: MMR Vaccines Market, Global, Revenue Forecasts ($bn), 2007-2017 69
Figure 41: MMR Vaccines Market, Global, Average Cost of Vaccination ($), 2007-2017 70
Figure 42: MMR Vaccines Market, Global, Target Population (million), 2007-2017 71
Figure 43: Pediatric Vaccines Market, Global, Pipeline Molecules by Phase, (%), 2011 74
Figure 44: Pediatric Vaccines Market, Global, Pipeline Molecules by Indication, (%), 2011 75
Figure 45: Hepatitis A Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011 76
Figure 46: Hepatitis B Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011 77
Figure 47: Polio Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011 83
Figure 48: Rotavirus Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011 86
Figure 49: DTaP Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011 88
Figure 50: MMR Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011 92
Figure 51: Pediatric Vaccines Market, Global, Novartis, Company Profile, 2011 94
Figure 52: Pediatric Vaccines Market, Global, Novartis, SWOT Analysis, 2011 95
Figure 53: Pediatric Vaccines Market, Global, GlaxoSmithKline, Company Profile, 2011 96
Figure 54: Pediatric Vaccines Market, Global, GlaxoSmithKline, SWOT Analysis, 2011 97
Figure 55: Pediatric Vaccines Market, Global, Sanofi Pasteur MSD, Company Profile, 2011 97
Figure 56: Pediatric Vaccines Market, Global, Sanofi Pasteur MSD, SWOT Analysis, 2011 98
Figure 57: Pediatric Vaccines Market, Global, Merck, Company Profile, 2011 99
Figure 58: Pediatric Vaccines Market, Global, Merck, SWOT Analysis, 2011 100
Figure 59: Pediatric Vaccines Market, Global, Pfizer, Company Profile, 2011 100
Figure 60: Pediatric Vaccines Market, Global, Pfizer, SWOT Analysis, 2011 101
Figure 61: Pediatric Vaccines Market, Global, Deals by Type, (%), 2004-2011 102
Figure 62: Pediatric Vaccines Market, Global, Deals by Geography, (%), 2004-2011 103
Figure 63: Pediatric Vaccines Market, Global, M&A Deals, 2004-2011 104
Figure 64: Pediatric Vaccines Market, Global, M&A Deals by Indication (%), 2004-2011 105
Figure 65: Pediatric Vaccines Market, Global, M&A Deals by Year, 2004-2011 106
Figure 66: Pediatric Vaccines Market, Global, M&A Deals by Geography (%), 2004-2011 107
Figure 67: Pediatric Vaccines Market, Global, M&A Deals by Value (%), 2004-2011 108
Figure 68: Pediatric Vaccines Market, Global, Licensing Agreements by Indication (%), 2004-2011 110
Figure 69: Pediatric Vaccines Market, Global, Licensing Agreements by Year, 2004-2011 112
Figure 70: Pediatric Vaccines Market, Global, Licensing Agreements by Geography (%), 2004-2011 113
Figure 71: Pediatric Vaccines Market, Global, Licensing Agreements by Value (%), 2004-2011 114
Figure 72: Pediatric Vaccines Market, Global, Co-Development Deals by Indication (%), 2004-2011 117
Figure 73: Pediatric Vaccines Market, Global, Co-Development Deals by Year, 2004-2011 118
Figure 74: Pediatric Vaccines Market, Global, Co-Development Deals by Geography, 2004-2011 119

Upcoming Reports:

Poland: vodka market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the vodka market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the vodka market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of the main market...
Alpha-2 Antiplasmin Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Alpha-2 antiplasmin or plasmin inhibitor, is a type of glycoprotein synthesized by the liver, kidneys and other tissues of the body. It is a serine protease inhibitor which belongs to the Serpin superfamily that acts as the primary inhibitor of the serine protease plasmin. Fibrinolysis occurs due to the conversion of plasminogen to serine protease plasmin by plasminogen activator. Deficiency of Alpha 2 antiplasmin causes a bleeding disorder owing to the increase fibrinolysis. Alpha-2 antiplasmin is the protein responsible for the degradation of fibrin clots and inhibition of fibrinolysis....
Bio Based Lubricants Market - Global Industry Analysis, Size, Share, Trends, Analysis, Growth And Forecast 2014 - 2020
By - Transparency Market Research
In the last two decades, concern and awareness on the use of products derived from petroleum and their adverse impact on the environment have created an opportunity to produce environmental friendly lubricants. The advantages of environmentally acceptable products include minimal health and safety risks and less pollution. Lubricants affect the environment at all stages of production, use, and disposal and should be non-toxic to humans through contact and inhalation during production and use. Accidental losses that arise during spill can cause ecological disaster to environmentally...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

A Health Tech Incubator Started by GE Healthcare
Oct 30, 2014  
For the very first time, a health tech start up campus has been established by GE Healthcare at its headquarters at Helsinki, Finland. This area already has about twenty such healthcare start ups that are working on cloud services, wireless technologies, apps, and sensors that aim at improving healthcare. The main rationale behind such a step is providing opportunities for further...
Net Earnings of DuPont Increases 52% despite Agricultural Turmoil
Oct 29, 2014  
DuPont - The Wilmington, Del-based leading chemical company faced decline of three percent sales to $7.5 billion in the quarter ending of September 30. The company’s third-quarter earnings were increased by 52 percent to $433 million albeit the slow global growth and agricultural downside.   The company witnessed the biggest drags from chemical sales with eight percent...
Appeal for Sanitization in Construction Industry through Government Regulations: CIOB Ghana
Oct 29, 2014  
Rockson Dogbegah - The Chairman of the Chartered Institute of Building Ghana commented that the construction industry needs a thorough cleaning up and assurance of proper growth. Mr. Dogbegah also said that a few factors are extremely important for a proper development in the construction industry. These include keen adherence to standards, supreme sense of professionalism, and sheer pursuance...
Facebook Hints of Rise in Expenses in 2015, Shares Drop
Oct 29, 2014  
Facebook has announced on Tuesday that it is prepping for a dramatic rise in spending in the year 2015. This warning has come combined with a projected slowdown in the company’s revenues after revenues were analyzed at the end of the third quarter of the year. The plans of such hefty spending in the next financial year by the company are indicative of stress in the investor...
Samsung Records Poorest Profits in Q3 2014
Oct 29, 2014  
In the quarter ending September 2014, Samsung Electronics Co. Ltd registered the smallest earnings ever in two years. The drop in earnings can be easily attributed to heavy competition from new Chinese devices and the Apple phones. The net income stood at US$4 billion for the South Korea-based company. Apple has been Samsung’s strongest contender ever since the latter entered the...